Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06019559 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833
A Phase 2 study, sponsored by Kallyope.
- Completed
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
NCT06019559: Completed Phase 2 study, sponsored by Kallyope.
NCT06019559 is a Phase 2 study that has completed, run by Kallyope. The registered enrollment target is 155 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06019559, a Phase 2 study, has completed, sponsored by Kallyope.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
Study Summary
This is a study to evaluate the safety and efficacy of K-757 alone and in combination with K-833 versus placebo in participants who are obese.
Interventions
- DRUG Matching placebo to K-757 and matching placebo to K-833
- DRUG K-757 120 mg BID and K-833 100 mg BID
- DRUG K-757 120 mg BID and matching placebo to K-833
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2023-09-15 |
| Est. Completion | 2024-02-19 |
| Phase | Phase 2 |
What the finished NCT06019559 record still lists
NCT06019559 is an interventional study that assigns participants to a tested intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% higher).
The record links to 0 conditions, and to 3 interventions - of which Matching placebo to K-757 and matching placebo to K-833 is the first listed.
NCT06019559 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06019559 about?
NCT06019559 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833". This is a study to evaluate the safety and efficacy of K-757 alone and in combination with K-833 versus placebo in participants who are obese.
What is the current status of trial NCT06019559?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2023-09-15. Estimated completion is 2024-02-19.
What interventions are being tested in trial NCT06019559?
The interventions under investigation include: Matching placebo to K-757 and matching placebo to K-833 (DRUG), K-757 120 mg BID and K-833 100 mg BID (DRUG), K-757 120 mg BID and matching placebo to K-833 (DRUG).
Who is sponsoring clinical trial NCT06019559?
This trial is sponsored by Kallyope, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06019559's enrollment target sits among peer trials
155 448th of 2000 higher than 1,553 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03223610 · 155 participants · Phase 1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- NCT05072483 · 155 participants
Natural History Study of CADASIL
- NCT05086497 · 155 participants · NA
WBSI Guided Personalized Delivery of TTFields
- NCT05412069 · 155 participants · NA
Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI